Affinia Therapeutics

Affinia extends our deepest gratitude to Katherine High, MD, world-renowned #genetherapy thoughtleader and visiting professor at The Rockefeller University, for delivering a captivating talk to our company, “Turning Genes into Medicines: Highlights and Hurdles in Development of AAV Products for Genetic Blindness and Hemophilia.” Pearls of wisdom that can only come from someone who has successfully developed multiple #AAV #genetherapies. #rationallydesignedAAV 

Affinia at #BIO24. Our head of BD Alanna Murday is excited to see/meet industry colleagues, partners, and make new acquaintances. Wishing all a successful conference! #genetherapy #rationallydesignedcapsids

Affinia at #BIO24. Our head of BD Alanna Murday is excited to see/meet industry colleagues, partners, and make new acquaintances. Wishing all a successful conference! #genetherapy #rationallydesignedcapsids

Affinia is pleased to announce that our CEO Rick Modi and CDO Laura Richman, MBA, PhD, DVM, DACVP will participate in one-on-one meetings with investors at the 2024 Jefferies Global Healthcare Conference. #genetherapy #rationallydesignedcapsids https://bit.ly/3Knkmjr

Let us never forget that that very freedom we enjoy came at the expense of the brave men and women who lost their lives fighting to protect it. Affinia wishes everyone a safe #MemorialDay holiday weekend.  

Affinia is excited to be featured in the latest Mass General Brigham Ventures Catalysis newsletter. #genetherapy #rationallydesignedcapsids

Affinia is proud to announce new preclinical data on our novel AAV capsids for genetic cardiomyopathies and diseases of the CNS such as #ALS, as well as our high-yield manufacturing process being presented at #ASGCT24. Of note, our novel cardiotropic capsids transduce more than 90% of cardiomyocytes in NHPs and detarget the liver and DRG and show safety and efficacy in a mouse model of cardiac dysfunction. And, our novel BBB-penetrant capsid transduces more than 50% of neurons in NHPs across spinal cord, cortex, and deep-brain regions and detargets the liver and DRG, and shows greater than 50% reduction of Ataxin-2, a gene believed to be involved in sporadic #ALS. Read more in our press release https://bit.ly/4aknE1k #GeneTherapy #rationallydesignedcapsids

Affinia at #ASGCT2024! We are excited to present new data on our next-generation novel BBB-penetrant #AAV capsid providing proof of concept for the treatment of multiple #CNS diseases including ALS, as well as our proprietary manufacturing process in HEK-293 suspension cells. These new data will be delivered in oral presentations tomorrow (Friday, May 10). One oral presentation (abstract 304) showcases data from Affinia’s novel, BBB-penetrant AAV capsid with a potential therapeutic application to sporadic ALS. The data show that the capsid delivers an Ataxin-2 (Atxn2) microRNA cargo that adequately decreases Atxn2 mRNA in non-human primates. Ataxin-2 is a gene believed to be involved in sporadic ALS. Another oral presentation (abstract 290) features Affinia’s proprietary manufacturing process in HEK-293 suspension cells, yielding greater than 50% full capsids with greater than 1e15vg/L at harvest, with broad applicability across conventional and novel AAV capsids and with significant potential cost advantages relative to other gene therapies. We look forward to seeing you there! #GeneTherapy #rationallydesignedcapsids

#ASGCT2024 kicks off tomorrow! Affinia Therapeutics is looking forward to presenting new data on our next-generation novel cardiotropic and BBB-penetrant #AAV capsids and preclinical efficacy and safety in genetic cardiomyopathies and sporadic ALS. Our poster presentations take place on Wednesday, May 8 and Thursday, May 9. Our first poster on May 8 showcases data that confirm the safety and therapeutic efficacy of a novel cardiotropic AAV capsid in an animal model of cardiac dysfunction with a potential therapeutic application in genetic cardiomyopathies (abstract 605). Our next poster presentation on May 9 features a screening platform for the discovery of novel, next-generation CNS tropic capsids, based on binding to cell receptors that facilitate BBB transcytosis and with potential applicability to non-AAV targeted delivery modalities (abstract 982). We look forward to seeing you there! #GeneTherapy #rationallydesignedcapsids

Affinia Therapeutics is excited to unveil new data on its next-generation novel cardiotropic and BBB-penetrant #AAV capsids and preclinical efficacy and safety in genetic cardiomyopathies and sporadic #ALS featured in two oral presentations and two posters at the 2024 Annual Meeting of the American Society of Gene & Cell Therapy (#ASGCT2024) taking place May 7-11 in Baltimore, MD, and virtually.    “We are excited to unveil data on our next-generation bespoke capsids that demonstrate robust cardiac transduction while detargeting the liver and DRG. Similarly, our BBB-penetrant capsid detargets the liver and DRG and shows a promising profile for treating multiple CNS diseases,” said Rick Modi, Affinia’s Chief Executive Officer. “Our initial preclinical results in genetic cardiomyopathies and sporadic ALS are in line with our purpose to bring life-changing gene therapies to people suffering from life-threatening and disabling diseases."   In addition, Affinia has been invited to present on the #rationaldesign of cardiotropic capsids that detarget the liver and DRG, and two members from its leadership team have been invited to chair scientific sessions.    You can learn more in our release https://bit.ly/3U8V251   #genetherapy #rationallydesignedcapsids